English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn a new Annals ‘Beyond the Guidelines’ feature, two physicians experienced in HIV antiretroviral pre-exposure prophylaxis (PrEP) debate how best to identify those patients who might benefit from PrEP, how to decide what regimen to use, and how to monitor therapy.
Tag: PREP
NIH grants support UCLA and Charles Drew University researchers’ efforts to end HIV epidemic
The National Institutes of Health (NIH) has granted $2.1 million to UCLA’s Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) and the UCLA-CDU Center for AIDS Research (CFAR) to support four research projects and an implementation science consultation hub.
Pride Month: Penn Nursing Experts Available to Discuss LGBTQ+ Issues
Topics Include: Eidos LGBTQ+ Health Initiative, Policy, HIV/AIDS, Sex Communication, Mental Health, Disparities, PrEP, Workplace Inclusion Experts Available Via Virtual/Phone/Email Interviews The Eidos LGBTQ+ Health Initiative at the University of Pennsylvania School of Nursing cultivates and engages emerging and experienced…
Researchers Receive $4.2M Grant to Improve PrEP Access and Prevent New HIV Infections
Bronx county has the country’s fifth-highest rate of HIV diagnosis—but the lowest rate in New York State for use of HIV pre-exposure prophylaxis (PrEP), medications that are extremely effective in preventing HIV infection. Physician-researchers at Albert Einstein College of Medicine and Montefiore Health System have received a five-year, $4.2 million grant from the National Institutes of Health to compare two strategies for improving PrEP access and use in the Bronx.
Journal Special Issue Offers Evidence and Guidance Supporting National PrEP Program to Turn Tide on HIV
Special issue includes research and commentary addressing important considerations for national PrEP program that would lower prices and expand access.
PrEP Stigma Still High Among Men Who Have Sex With Men
Many male couples in the U.S. seem to be underestimating the effectiveness of HIV pre-exposure prophylaxis (PrEP) for HIV prevention, and educating partners together could improve the number of male couples who decide to adopt PrEP. These conclusions come from a study reported in the July/August issue of The Journal of the Association of Nurses in AIDS Care (JANAC), the official journal of the Association of Nurses in AIDS Care. JANAC is published in the Lippincott portfolio by Wolters Kluwer.
New Study Suggests Healthcare Provider Biases Can Impact a Patient’s Access to Preventative HIV Drug
A new study published today reveals systematic biases among primary and HIV care providers about people who inject drugs and how those biases may impact access to pre-exposure prophylaxis (PrEP), a preventive, prescription-based medication that significantly reduces the risk of HIV infection through sexual behavior and injection practices.
Article of the Year!
The Association of Nurses in AIDS Care (ANAC) honors research led by Anne Teitelman, PhD, FNP-BC, FAANP, FAAN, Associate Professor Emerita in Penn Nursing’s Department of Family and Community Health, as the 2021 JANAC (Journal of the Association of Nurses in AIDS Care) Article of the Year.
Stigma Remains a Barrier in HIV Prevention and Treatment
Stigma and discrimination, such as homophobia and racism, impede engagement in HIV prevention and use of biomedical tools for treatment in both HIV-negative and HIV-positive gay and bisexual men, according to a Rutgers study.
People at High Risk for HIV Know about Prevention Pill, But Use Remains Low
Cisgender sexual minority men and transgender women are aware of pre-exposure prophylaxis (PrEP), a daily pill for HIV-negative people to prevent HIV infection, but few are currently taking it, according to researchers at Rutgers.
The study, published in the journal AIDS and Behavior, surveyed 202 young sexual minority men and transgender women – two high-priority populations for HIV prevention – to better understand why some were more likely than others to be taking PrEP.
Study Finds Low Awareness of PrEP, the Highly Effective Medication that Protects Individuals from HIV
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that just under 20 percent of HIV-uninfected patients visiting Baltimore sexual health clinics were aware of pre-exposure prophylaxis medication (PrEP), a daily regimen that decreases a person’s risk of contracting HIV from sex by more than 90 percent.
April 2021 Issue of AJPH highlights COVID-19 as it relates to unemployment and excess deaths in Florida, Medicaid expansion, and misinformation spread by crowdfunding campaigns
April 2021 highlights from AJPH Issue includes COVID-19-related articles around deaths linked to unemployment, higher than reported death toll in Florida and crowdfunding campaigns spreading misinformation
State Laws Key to HIV Prevention Efforts
HIV prevention remains a public health priority in the United States. Pre-exposure prophylaxis (PrEP) is a drug regimen recommended for individuals who have engaged in behaviors that place them at elevated risk for HIV. When used consistently, daily oral PrEP has been shown to reduce HIV transmission by 99 percent. However, despite increases in PrEP awareness and uptake over the past several years, data show that four of five people who could benefit from PrEP did not access the medication in 2018.
Short-Term Use of HIV-Prevention Medication Protects At-Risk Men on Vacation
Men at particular risk for HIV are very likely to consistently take prevention medication during vacations when their odds of contracting the virus are higher, according to a new study.
Twitter chat with HIV/AIDS experts from the Johns Hopkins School of Nursing, Nov. 26, to prepare for World AIDS Day
The Johns Hopkins School of Nursing @JHUNursing is hosting a Twitter Chat in advance of World AIDS Day featuring its practitioners, researchers, and experts in HIV care, prevention, and science. Tuesday, November 26, 4:00 pm, EST Join and ask questions…